| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/BJH.13013 |
| P698 | PubMed publication ID | 24975213 |
| P50 | author | Rosemary Gale | Q59828924 |
| David C Linch | Q89467453 | ||
| P2093 | author name string | Chloe Stengel | |
| Dennis Huszar | |||
| Barry R Davies | |||
| Asim Khwaja | |||
| Koremu Meja | |||
| Rob Sellar | |||
| P2860 | cites work | mTOR signaling in growth control and disease | Q24634174 |
| Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases | Q27681337 | ||
| Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background | Q27851716 | ||
| The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death | Q28204906 | ||
| PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells | Q28237807 | ||
| Targeting the phosphoinositide 3-kinase pathway in cancer | Q29615809 | ||
| Drug combination studies and their synergy quantification using the Chou-Talalay method | Q29617422 | ||
| Tumour heterogeneity and cancer cell plasticity | Q29617990 | ||
| Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. | Q33882849 | ||
| Modeling pO(2) distributions in the bone marrow hematopoietic compartment. I. Krogh's model | Q34176018 | ||
| Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia | Q35125923 | ||
| Delving deeper: MCL-1's contributions to normal and cancer biology | Q36494824 | ||
| Genome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia | Q37226744 | ||
| AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia | Q37564783 | ||
| For better or for worse: the role of Pim oncogenes in tumorigenesis | Q37820056 | ||
| The PIM family of serine/threonine kinases in cancer | Q38098139 | ||
| Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation | Q38266874 | ||
| Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations | Q38360085 | ||
| Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype | Q39380262 | ||
| Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. | Q39844632 | ||
| Activating alleles of JAK3 in acute megakaryoblastic leukemia | Q40255542 | ||
| JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders | Q40330808 | ||
| Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival | Q40501190 | ||
| Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias | Q40615155 | ||
| Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival | Q41868647 | ||
| Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors | Q41907705 | ||
| Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy | Q42716236 | ||
| Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site | Q44997396 | ||
| Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region | Q45796591 | ||
| Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors | Q45846353 | ||
| The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells. | Q50502283 | ||
| Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma | Q57767618 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| cytotoxicity | Q246181 | ||
| P304 | page(s) | 69-79 | |
| P577 | publication date | 2014-06-30 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways | |
| P478 | volume | 167 |
| Q38798340 | Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma |
| Q38803880 | Elevated PIM2 gene expression is associated with poor survival of patients with acute myeloid leukemia. |
| Q38892684 | FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia |
| Q52366350 | FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway. |
| Q39326047 | Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia |
| Q37437166 | Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling |
| Q92545473 | Isoferulic acid inhibits human leukemia cell growth through induction of G2/M‑phase arrest and inhibition of Akt/mTOR signaling |
| Q41190391 | Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma |
| Q52846906 | Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. |
| Q38370023 | PIM kinase (and Akt) biology and signaling in tumors. |
| Q64100912 | PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells |
| Q54976784 | Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells. |
| Q39716970 | Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells. |
| Q90240397 | Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth |
| Q38285805 | Pim kinases in hematological malignancies: where are we now and where are we going? |
| Q55496770 | Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies. |
| Q89637594 | Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer |
| Q42380771 | Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia |
| Q50204389 | Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. |
| Q42702750 | Synergistic induction of cell death in haematological malignancies by combined phosphoinositide-3-kinase and BET bromodomain inhibition |
| Q33822197 | Synergistic interactions with PI3K inhibition that induce apoptosis. |
| Q40591054 | Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer |
| Q99549077 | Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence |
| Q36214081 | Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia |
| Q26799499 | Targeting the Pim kinases in multiple myeloma |
| Q36545566 | The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells |
| Q92052566 | The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma |
| Q38262117 | The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression |
Search more.